OBI Pharma Signs Exclusive Agreement with Merck for Antibiotic Drug

OBI Pharma of Taiwan signed an agreement with MSD, known as Merck in the US, transferring exclusive rights to develop and commercialize an antibiotic drug Dificid® (fidaxomicin) in Taiwan to MSD. OBI Pharma will receive an initial up-front payment of $3.0 million plus royalties and milestone payments from MSD. MSD will be responsible for all future costs associated with commercialization, development, and manufacturing of Dificid in Taiwan. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.